FINWIRES · TerminalLIVE
FINWIRES

EMEA石油最新情報:イラン戦争の最中、UAEのOPEC離脱で原油価格が上昇

By

-- 水曜日の原油価格は上昇した。エネルギー市場は、アラブ首長国連邦(UAE)のOPECからの歴史的な離脱と、ホルムズ海峡における海上封鎖の強化という二重の衝撃に反応した。 ブレント原油先物価格は4.5%上昇し、1バレル116.22ドルとなった。ムルバン原油先物価格は2.5%上昇し、1バレル109.31ドルとなった。 この急騰は、UAEが5月1日付でOPECおよびOPECプラスからの離脱を正式に発表し、世界の石油カルテルに歴史的な打撃を与えたことを受けてのものだ。 スハイル・アル・マズルーイ・エネルギー相は、この動きは「政策主導の進化」であり、生産割当量を回避して世界の石油埋蔵量を再構築し、国内の生産能力を収益化することを目的としたものだと述べた。 リスタッド・エナジーのストラテジストは、原油埋蔵量が減少している時期にUAEがOPECを離脱したことで、ますます分断され供給不足に陥る世界市場をOPECが今後どのように管理していくのか、重大な疑問が生じていると警告している。 ホルムズ海峡が事実上閉鎖されたままであるため、現在の供給見通しは依然として厳しい。 トランプ米大統領は火曜日、イラン政権は「崩壊状態」にあり、海峡の再開を目指しているとソーシャルメディアで主張する一方で、側近に対しイランに対する「長期封鎖」の準備をするよう指示したと報じられている。 強気相場を後押しする要因として、米国石油協会(API)のデータによると、4月24日までの1週間で米国の原油在庫は179万バレル減少した。 原油市場は現在、水曜日に発表予定の米国エネルギー情報局(EIA)の石油在庫報告を待っている。 「トレーダーたちは今、和平交渉の次の段階と、堅調な輸出需要の中で米国の在庫がどれほど急速に減少しているかを示すさらなる兆候として、本日発表される米国の在庫報告に注目している」とサクソバンクのアナリストは述べた。

Related Articles

Research

Research Alert: CFRA Downgrades Rating To Sell From Hold On Shares Of Essex Property Trust, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target by $15 to $250 using a narrower equity risk premium and a forward P/FFO of 15.5x, which is in line with the multifamily residential REIT average. We keep our 2026 FFO estimate at $16.15 and lower 2027's by $0.05 to $16.45 on respective revenue projections of $1.94B and $1.98B. Rental revenue is not yet rebounding to historical growth levels. Across the industry, we are seeing inflation in key operating expenses exceeding revenue growth, and this leads to modest gains in cash NOI growth Y/Y. We expect these market conditions to continue as pricing power for ESS and its peers seems to have eased. In particular, ESS has a West Coast portfolio profile that is exposed to significant job layoffs in the technology sector. In our opinion, we have not yet seen the tail risk of major announcements just released in recent weeks. ESS has the challenge of complying with strict housing guidelines in California, leading to the trust historically underperforming peers in other parts of the country.

$ESS
Research

Research Alert: CFRA Keeps Buy Rating On Shares Of Biogen Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target at $236, 13.8x our new 2027 EPS view, a discount to BIIB's five-year historical forward P/E average of 14.1x. We lower our 2026 EPS view to $15.24 from $16.14 to adjust for the impact from acquired IPR&D. We keep our 2027 EPS view at $17.16. BIIB reported a strong start to 2026, with sales of $2.5B and adjusted EPS of $3.57. We see a successful stabilization of the business after years of decline, due to a 12% Y/Y increase in the growth products portfolio. In our view, during the analyst call, management presented a clear strategic vision centered on the pending $5.6B acquisition of Apellis, expected to close in Q2, which can transform BIIB into a growth company by adding two commercial assets, Syfovre and Empaveli. We think the Apellis deal could bridge a revenue gap until 2028, when the company's late-stage pipeline matures. Via this acquisition, BIIB also gains nephrology expertise and an established infrastructure, which could set its key asset Felzartamab launch for success.

$BIIB
Australia

Starbucks to Sustain Sales Momentum; to Focus on Margins in H2, UBS Says

Starbucks (SBUX) is expected to maintain solid sales momentum on its turnaround strategy, though investor focus is shifting toward margin recovery in H2, UBS said in a note on Wednesday.The brokerage said strong transaction-driven comparable sales growth in Q2 reflected improvements in operations, menu innovation and updated loyalty program.Looking ahead, UBS said continued execution on initiatives such as afternoon beverage platforms, loyalty enhancements, store closures and operational improvements should support sales into H2.UBS also expects margin expansion later in the year, supported by sales leverage, cost savings and easing pressures from tariffs and coffee costs.UBS raised the price target on the stock to $105 from $100 but maintained a neutral rating.Price: $106.10, Change: $+8.82, Percent Change: +9.06%

$SBUX